Heron Therapeutics Launches Private Infrastructure Investment Strategy for Accredited Investors

Heron Therapeutics Launches Innovative Private Infrastructure Investment Strategy

Heron Therapeutics announces the launch of a new private infrastructure investing strategy, marking a significant development in the company’s offerings. This initiative allows accredited individual investors and family offices to invest in a diversified portfolio composed of over 1,000 infrastructure assets. By connecting these investors with five experienced fund managers—each boasting an average of 20 years in the sector—the company enhances its investment platform through a proprietary fund scoring process that may incorporate additional managers in the future. This strategic move not only broadens Heron’s investment options but also positions the company to capitalize on the growing interest in alternative investments.

The newly introduced strategy has already demonstrated promising results, with the underlying private infrastructure funds achieving an average annualized return of 13.5% after fees since their inception. CEO Mike Sall notes that this launch significantly enhances the Heron platform, which now features exposure to 20 private market funds selected through a rigorous proprietary ranking system. This development is particularly timely, as it provides investors with avenues to achieve long-term returns while effectively hedging against inflation—an increasingly important consideration in today’s economic landscape. The private infrastructure strategy complements Heron’s existing offerings of private credit and private equity, thereby solidifying the company’s commitment to delivering comprehensive alternative investment solutions.

The portfolio of the private infrastructure strategy spans various sectors, including power generation, transportation, telecommunications, and digital infrastructure. This diversity not only accommodates different risk appetites but also capitalizes on the historical resilience of private infrastructure as an asset class, especially during inflationary periods and market downturns. Analysts predict that 2026 may emerge as a pivotal year for private infrastructure investments, driven by growth in sectors such as power generation and logistics. By providing detailed insights into this evolving landscape, Heron Therapeutics positions itself as a frontrunner in facilitating investor access to high-potential opportunities.

In addition to the launch, Heron's commitment to educating investors about the benefits of private infrastructure investments is evident through supplementary articles, such as "Why invest in private infrastructure in 2026? 3 charts for investors." This resource outlines the advantages of diversifying beyond public markets, further reinforcing the company’s role as a key player in alternative investment strategies. Overall, the launch of the private infrastructure strategy represents a strategic expansion for Heron Therapeutics, aligning with current market trends and investor needs.